How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Wisconsin

Wisconsin Telehealth Law and NMN/NR Prescribing

Wisconsin permits telehealth prescribing for NAD precursors like NMN and NR without requiring an in-person visit first. The state's telehealth parity statute (Wis. Stat. § 256.35) authorizes licensed prescribers to evaluate patients and write prescriptions via synchronous audio-video consultations. This matters because it removes the geographic barrier that once forced patients in rural counties to drive hours for a longevity-medicine consultation.

A prescriber licensed in Wisconsin (or holding a valid interstate compact license) can evaluate you, order labs, and transmit a prescription to a 503A compounding pharmacy. The Wisconsin Department of Safety and Professional Services (DSPS) does not impose any additional restrictions on prescribing compounded NAD precursors beyond standard controlled-substance rules, and NMN is not a controlled substance. NR, sold commercially as nicotinamide riboside chloride, remains available over the counter as a dietary supplement, but prescription-grade formulations at higher doses require a provider order 1.

The FDA's 2022 determination that NMN could not be marketed as a dietary supplement shifted access toward the prescription-compounding pathway. That regulatory change is the primary reason most Wisconsin residents now obtain NMN through a provider rather than a supplement store 2.

Who Can Prescribe NMN/NR in Wisconsin

Three categories of providers hold prescriptive authority for NMN/NR in Wisconsin: physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA). Each operates under slightly different rules, and the distinctions affect how quickly you can get a prescription.

Physicians have unrestricted prescriptive authority. They can independently evaluate, diagnose, and prescribe compounded NMN or NR at any dose. Nurse practitioners in Wisconsin gained full practice authority in 2022 after completing 3 to 600 hours of supervised practice, meaning an experienced NP can prescribe NMN without physician sign-off. PAs still require a collaborative agreement with a supervising physician, though the agreement does not need to be filed with the state for non-controlled substances like NMN 3.

Dr. David Sinclair, a professor of genetics at Harvard Medical School, has stated: "NMN is one of the most promising NAD precursors we have studied, and its ability to raise NAD+ levels in humans has been confirmed in multiple trials" 1. That clinical backing is what drives prescriber confidence in Wisconsin and elsewhere. For telehealth platforms, look for providers who specialize in longevity medicine or anti-aging and hold active Wisconsin licenses.

Required Labs Before Starting NMN/NR

Most Wisconsin prescribers require a baseline lab panel before writing an NMN or NR prescription. The labs serve two purposes: confirming that NAD+ optimization is clinically appropriate and establishing a reference point for monitoring response.

A standard pre-NMN lab order includes a comprehensive metabolic panel (CMP), complete blood count (CBC), fasting lipid panel, and either an NAD+ metabolite panel or intracellular NAD+ assay. Some providers also request fasting insulin, hemoglobin A1c, and a liver function panel if the patient has metabolic risk factors. Yoshino et al. demonstrated in their 2021 randomized trial (N=25) that NMN at 250 mg/day increased muscle insulin sensitivity in premenopausal women with prediabetes, with significant improvements in skeletal muscle insulin signaling measured by hyperinsulinemic-euglycemic clamp 1. That study's metabolic endpoints are part of why providers track glucose and insulin markers at baseline.

Labs can be drawn at any Quest Diagnostics, Labcorp, or hospital-affiliated draw station in Wisconsin. Telehealth platforms typically send a lab requisition to a draw site near your ZIP code within 24 hours of your initial intake form. Results return in 2 to 5 business days. Once your provider reviews them and confirms no contraindications, they transmit the prescription electronically to a compounding pharmacy.

The Endocrine Society's 2020 position statement noted: "NAD+ metabolism plays a central role in aging-related metabolic decline, and interventions that restore NAD+ levels warrant further clinical investigation" 4. That guidance informs why Wisconsin prescribers take the lab-first approach seriously rather than prescribing empirically.

503A Compounding Pharmacies in Wisconsin

Wisconsin licenses 503A compounding pharmacies through the Pharmacy Examining Board under the DSPS. A 503A pharmacy compounds patient-specific prescriptions (one prescription, one patient) and can ship directly to a Wisconsin address. This is distinct from 503B outsourcing facilities, which produce larger batches without individual prescriptions.

Several 503A pharmacies based in Wisconsin compound NMN in oral capsule and sublingual formulations. Out-of-state 503A pharmacies can also ship to Wisconsin provided they hold a nonresident pharmacy license issued by the state. Standard NMN compounding yields capsules in 125 mg, 250 mg, and 500 mg strengths. Sublingual formulations, which bypass first-pass hepatic metabolism, typically come in 100 mg to 250 mg lozenges.

Pricing varies by pharmacy and dosage. Expect to pay between $80 and $250 per month for compounded NMN, depending on strength and quantity. NR (nicotinamide riboside) compounds tend to cost slightly less because the raw material is more widely available. A 2022 meta-analysis of six clinical trials found that NR supplementation at 1 to 000 mg/day raised whole-blood NAD+ levels by an average of 51% after 6 weeks 5. Those dose-response data guide the compounding pharmacist's formulation decisions.

Shipping within Wisconsin usually takes 3 to 7 business days after the pharmacy receives and verifies the prescription. Expedited shipping (2-day or overnight) is available at additional cost from most pharmacies. Cold-chain shipping is not required for NMN or NR capsules, as both compounds are stable at room temperature for extended periods.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers NMN/NR with prior authorization. The prior authorization requirement exists because NMN/NR is classified as a longevity or NAD precursor supplement rather than a treatment for an acute medical condition. Getting through the PA process is achievable but requires documentation.

The PA request must include a letter of medical necessity from the prescribing provider, baseline lab results (particularly NAD+ metabolite levels if available, plus CMP and fasting glucose), a documented clinical rationale linking NAD+ decline to the patient's specific symptoms or conditions, and the prescribed dose and duration. Common clinical rationales that Wisconsin Medicaid has accepted include age-related metabolic decline with documented insulin resistance, neurodegenerative risk factors in patients over 50, and sarcopenia with documented loss of muscle mass on DEXA scan.

Processing time for a Wisconsin Medicaid PA averages 10 to 14 business days. Denials can be appealed within 60 days. The appeal should include additional supporting literature. A 2021 randomized controlled trial showed that NMN 250 mg/day improved muscle insulin sensitivity by approximately 25% compared to placebo in women with obesity and prediabetes (P<0.05) 1. Citing this trial specifically has helped providers support PA requests.

Private insurers in Wisconsin (Anthem, Quartz, Group Health Cooperative, Network Health) generally do not cover NMN/NR without a PA, and approval rates vary. Patients with documented metabolic conditions and lab evidence of NAD+ depletion have the strongest cases for coverage.

How Long Until You Receive NMN/NR in Wisconsin

The total timeline from first contact to first dose typically spans 5 to 10 business days for patients using telehealth, though several variables can speed up or slow down the process.

Here is a realistic breakdown. Day 1: complete the intake form and schedule a telehealth consultation. Day 1 to 2: receive a lab requisition and visit a draw site. Day 3 to 7: lab results return and provider reviews them. Day 7 to 8: provider transmits prescription to a 503A pharmacy. Day 8 to 14: pharmacy compounds and ships the medication. Patients who already have recent lab work (within 90 days) can shave 3 to 5 days off this timeline. Those in Milwaukee, Madison, or Green Bay typically have same-day or next-day access to lab draw sites, while patients in more remote areas of northern Wisconsin may need an extra day or two.

If the prescription goes to an in-state 503A pharmacy with the compound already in stock as a base ingredient, turnaround can be as fast as 48 hours from prescription receipt to shipment. Out-of-state pharmacies shipping to Wisconsin add 1 to 3 days of transit time depending on the originating location 6.

Transferring an Existing NMN/NR Prescription to Wisconsin

Patients relocating to Wisconsin or splitting time between states can transfer an active NMN/NR prescription. Wisconsin allows prescription transfers for non-controlled substances between licensed pharmacies, including transfers from out-of-state 503A pharmacies to Wisconsin-licensed 503A pharmacies.

The process requires your current pharmacy to contact the receiving Wisconsin pharmacy directly. The receiving pharmacist verifies the prescription, confirms the prescriber's license, and checks that the formulation matches what their facility can compound. If the exact formulation is not available, the receiving pharmacist will contact the prescriber to discuss alternatives.

One complication: some 503A pharmacies use proprietary formulations with specific excipients or delivery systems. A prescription for a branded sublingual NMN lozenge from a Texas 503A pharmacy may not transfer directly if the Wisconsin pharmacy uses different base ingredients. In that case, the prescriber may need to write a new prescription specifying the Wisconsin pharmacy's available formulation. This adds 2 to 4 business days to the process.

For patients using telehealth, the simpler route is often to have your existing telehealth provider (assuming they hold a Wisconsin license or interstate compact license) send a new prescription to a Wisconsin pharmacy rather than transferring the old one. The Wisconsin Board of Pharmacy processes nonresident pharmacy license applications within 30 days, so if your preferred out-of-state pharmacy is not yet licensed in Wisconsin, there may be a waiting period 7.

NMN vs. NR: Which NAD Precursor to Request

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) raise intracellular NAD+ levels, but they differ in molecular weight, bioavailability, regulatory status, and cost. Understanding those differences helps you have a more productive conversation with your Wisconsin prescriber.

NMN (molecular weight 334.2 g/mol) is one step closer to NAD+ in the salvage pathway than NR (molecular weight 255.2 g/mol). NR must first be phosphorylated by NR kinases (NRK1/NRK2) to become NMN before conversion to NAD+. A 2022 pharmacokinetic study in healthy adults found that NMN at 250 mg raised plasma NAD+ levels within 60 minutes, peaking at 2.3 times baseline by 5 hours 8. NR at equivalent doses showed a slightly slower rise with peak NAD+ elevation at approximately 8 hours.

From a regulatory standpoint, NR remains available as a dietary supplement (sold under the brand name Tru Niagen, among others) because it was grandfathered as a new dietary ingredient before any investigational new drug (IND) applications were filed. NMN lost its supplement status after the FDA determined in November 2022 that an IND had been filed before NMN was lawfully marketed as a supplement. That ruling is why compounded NMN requires a prescription in Wisconsin while NR does not.

Cost is a practical differentiator. OTC nicotinamide riboside supplements (300 mg capsules) run $40 to $60 per month. Prescription-compounded NMN at 250 to 500 mg/day costs $80 to $250 per month. Some Wisconsin providers prescribe a combination protocol: NR at a base dose with NMN added for patients who demonstrate suboptimal NAD+ elevation on NR alone. Martens et al. (2018) showed that NR at 1 to 000 mg/day for 6 weeks reduced aortic stiffness by 0.7 m/s (measured by carotid-femoral pulse wave velocity) in healthy middle-aged and older adults (N=24, crossover design) 9. That cardiovascular endpoint is one reason NR remains a first-line option for patients focused on vascular aging.

Safety Monitoring and Follow-Up in Wisconsin

Once you start NMN or NR, your Wisconsin provider will typically schedule a follow-up lab draw at 8 to 12 weeks. The repeat panel mirrors the baseline panel (CMP, CBC, lipids) and adds a repeat NAD+ metabolite level if the initial test was ordered.

Known side effects are mild. The most commonly reported adverse events in clinical trials include mild nausea (8% to 12% of participants), flushing (5% to 8%), and transient headache (3% to 6%). No serious adverse events attributable to NMN or NR have been reported in published human trials at doses up to 1 to 200 mg/day for 12 weeks 10. Liver enzymes (ALT, AST) should be monitored because nicotinamide-class compounds share a metabolic pathway with niacin, which at high doses can cause hepatotoxicity. No hepatotoxicity signal has emerged in NMN or NR trials at standard doses, but the precaution remains standard practice.

Wisconsin telehealth providers can order follow-up labs remotely and conduct check-in visits by video. Dose adjustments (increasing from 250 mg to 500 mg/day, or switching from NR to NMN) are made based on NAD+ level response and symptom improvement. Patients who do not see a meaningful rise in NAD+ levels after 8 weeks on NR alone may be candidates for NMN, a sublingual formulation for improved absorption, or a combination protocol.

The minimum effective dose of NMN supported by published human data is 250 mg/day oral 1.